LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling

While the antiandrogen enzalutamide (Enz) extends the castration resistant prostate cancer (CRPC) patients’ survival an extra 4.8 months, it might also result in some adverse effects via inducing the neuroendocrine differentiation (NED). Here we found that lncRNA-p21 is highly expressed in the NEPC...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Jie, Wang, Keliang, Yeh, Shuyuan, Sun, Yin, Liang, Liang, Xiao, Yao, Xu, Wanhai, Niu, Yuanjie, Cheng, Liang, Maity, Sankar N., Jiang, Runze, Chang, Chawnshang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561926/
https://www.ncbi.nlm.nih.gov/pubmed/31189930
http://dx.doi.org/10.1038/s41467-019-09784-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561926/
https://www.ncbi.nlm.nih.gov/pubmed/31189930
http://dx.doi.org/10.1038/s41467-019-09784-9

Ejemplares similares